Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem

HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms

Kumar P. et al, (2024)

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.

Brimblecombe KR. et al, (2023), Eur J Neurosci

Kinetic insights into agonist-dependent signalling bias at the pro-inflammatory G-protein coupled receptor GPR84.

Luscombe VB. et al, (2023), Eur J Pharmacol, 956

Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.

Josa-Culleré L. et al, (2023), Eur J Med Chem, 258

Screening the Medicines for Malaria Pandemic Response Box chemical library onCaenorhabditis elegansidentifies re-profiled candidate anthelmintic drug leads

Nick M. et al, (2022)

A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2.

Bery N. et al, (2021), Sci Adv, 7

The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes.

Hua P. et al, (2020), Blood, 136, 2410 - 2415

Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.

Quevedo CE. et al, (2020), Bioorg Med Chem, 28

20 Years an Orphan: Is GPR84 a Plausible Medium-Chain Fatty Acid-Sensing Receptor?

Luscombe VB. et al, (2020), DNA Cell Biol, 39, 1926 - 1937

NMR waterLOGSY as An Assay in Drug Development Programmes for Detecting Protein-Ligand Interactions-NMR waterLOGSY.

Bataille CJR. et al, (2020), Bio Protoc, 10

Anthelmintic drug discovery: target identification, screening methods and the role of open science.

Partridge FA. et al, (2020), Beilstein J Org Chem, 16, 1203 - 1224

Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells

Jain AK. et al, (2020), ACS Applied Bio Materials

Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s

Brimblecombe K. et al, (2020)

Structural requirements for dihydrobenzoxazepinone anthelmintics: actions against medically important and model parasites - Trichuris muris, Brugia malayi, Heligmosomoides polygyrus and Schistosoma mansoni

Partridge F. et al, (2020)

A Biased Agonist at Immunometabolic Receptor GPR84 Causes Distinct Functional Effects in Macrophages.

Lucy D. et al, (2019), ACS Chem Biol, 14, 2055 - 2064

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.

Cruz-Migoni A. et al, (2019), Proc Natl Acad Sci U S A, 116, 2545 - 2550

Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors.

Stefaniak J. et al, (2018), ACS Chem Biol, 13, 2849 - 2854

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.

Quevedo CE. et al, (2018), Nat Commun, 9

Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.

Bery N. et al, (2018), Elife, 7

Load More

Include forthcoming?